What is the added benefit on top of guideline (IDF)-directed background medication?
The addition of pioglitazone to existing therapy was compared with current recommended therapy. The study demonstrated that pioglitazone protected against life-threatening cardiovascular outcomes (heart attacks, strokes, and deaths) while patients were being treated better than that achieved with usual standard of care in global communities. In the Steno-2 study, in which intensified multi-factorial intervention was compared with standard multi-factorial intervention, significantly fewer patients in the control group received statins, antihypertensives or antiplatelet therapy, whereas in PROactive, patients in both groups were receiving comparable multi-factorial interventions at baseline and at study end (statins, fibrates, anti-hypertensives, and anti-platelet therapy). Any effect of pioglitazone should therefore be considered as additional to these interventions. Use of anti-hypertensives and anti-platelet therapy was similar between PROactive and the intensive group in Steno-2.In P
